NXTC NextCure, Inc.

NASDAQ
$6.89

NextCure, Inc. (NXTC) is expected to report earnings on February 9, 2027, after the market close. The stock has had a Post-Earnings Announcement Drift (PEAD) of +20.2% since its last earnings release on November 10, 2026.

NextCure Missed Consensus Estimates
Tuesday, November 10, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.39

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.